Laura H Tang

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 32:1429-43. 2008
  2. ncbi Defining surgical indications for type I gastric carcinoid tumor
    Rebecca A Gladdy
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 16:3154-60. 2009
  3. ncbi Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 36:1761-70. 2012
  4. ncbi Epithelial neoplasms of the appendix
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1612-20. 2010
  5. ncbi Barrett's esophagus and adenocarcinoma of the gastroesophageal junction: a pathologic perspective
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C507, New York, NY 10021, USA
    Surg Oncol Clin N Am 15:715-32. 2006
  6. ncbi Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades
    Jordan M Winter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:169-75. 2012
  7. ncbi Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease
    K A Bickenbach
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
    Ann Surg Oncol 19:1663-9. 2012
  8. ncbi Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment
    Bridget N Fahy
    Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:1735-43. 2007
  9. ncbi Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 35:447-54. 2011
  10. ncbi Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 35:127-34. 2011

Detail Information

Publications44

  1. ncbi Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 32:1429-43. 2008
    ..Surgical management with right hemicolectomy is recommended after appendectomy for most cases, particularly those with an adenocarcinoma component (groups B and C)...
  2. ncbi Defining surgical indications for type I gastric carcinoid tumor
    Rebecca A Gladdy
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 16:3154-60. 2009
    ..The management of this indolent disease is controversial. The aim of this study was to evaluate endoscopic surveillance (ES) compare with surgical resection (SR) for type I GC...
  3. ncbi Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 36:1761-70. 2012
    ..Consequently, determination of therapeutic strategies should be guided by an amalgamation of clinicopathologic characteristics, including but not limited to the Ki67 index...
  4. ncbi Epithelial neoplasms of the appendix
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1612-20. 2010
    ....
  5. ncbi Barrett's esophagus and adenocarcinoma of the gastroesophageal junction: a pathologic perspective
    Laura H Tang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C507, New York, NY 10021, USA
    Surg Oncol Clin N Am 15:715-32. 2006
    ..The potential identification and isolation of markers for screening purposes and possibly prognostic information are areas of considerable clinical and scientific interest...
  6. ncbi Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades
    Jordan M Winter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:169-75. 2012
    ..The purpose of this study was to evaluate whether these improvements could be identified in a cohort of patients who underwent resection for pancreatic cancer at a single institution over three decades...
  7. ncbi Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease
    K A Bickenbach
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
    Ann Surg Oncol 19:1663-9. 2012
    ..The objective of this study was to evaluate outcome of initially unresectable patients who respond to multimodality therapy and undergo resection...
  8. ncbi Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment
    Bridget N Fahy
    Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:1735-43. 2007
    ..Predicting rectal carcinoid behavior based exclusively on tumor size is imprecise. We sought to identify factors associated with outcome and incorporate them into a pre-operative risk stratification scheme...
  9. ncbi Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 35:447-54. 2011
    ..However, whether biopsy samples can be reliably used for mismatch repair protein detection remains to be determined...
  10. ncbi Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 35:127-34. 2011
    ....
  11. ncbi Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center
    Jean M Butte
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Gastrointest Surg 15:350-7. 2011
    ..The aim of this study was to define the natural history and compare patient and tumor factors between patients with malignant and non-malignant disease...
  12. ncbi Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 33:1639-45. 2009
    ..Such a cost-effective approach carries significant implication, as immunohistochemistry is being widely used as first-line screening for HNPCC...
  13. ncbi Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma
    Nabil P Rizk
    Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Cancer Epidemiol Biomarkers Prev 21:482-6. 2012
    ..In this pilot study, we investigated whether tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's esophagus (BE) and in esophageal adenocarcinoma (EAC)...
  14. ncbi Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set
    David S Klimstra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 34:300-13. 2010
    ..Examination of the areas of disagreement reveals significant opportunities for collaborative study to resolve unanswered questions...
  15. ncbi DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases
    Narasimhan P Agaram
    Dept of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Am J Clin Pathol 133:772-80. 2010
    ..Typical MSI-high histologic features of CRC, such as increased TIL counts, seem to have similar yet subtly different implications in ampullary carcinoma...
  16. ncbi Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 32:719-31. 2008
    ..These tumors are clinically aggressive. Prospective studies using defined diagnostic criteria are needed to determine their biologic characteristics and optimal management...
  17. ncbi Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance
    Anne Lin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 38:850-6. 2007
    ..Further investigation on interaction between AMACR and other known colorectal cancer development pathways may provide new insights on colorectal carcinogenesis...
  18. ncbi Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?
    Cristina R Ferrone
    Department of Surgery, Memorial Sloan Kettering Cancer Center, Howard 1223, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:5609-15. 2007
    ..This study compares the prognostic value of a simplified staging and grading system with the WHO system in a large single-institution study...
  19. ncbi Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision
    Johan L Dikken
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Cancer 118:349-57. 2012
    ..The objective of the current study was to investigate the accuracy of preoperative histopathologic grading and the effect of preoperative grade on tumor stage/prognostic grouping...
  20. ncbi Squamous-cell carcinoma of the rectum: a rare but curable tumor
    Caio S R Nahas
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Dis Colon Rectum 50:1393-400. 2007
    ..This study was designed to evaluate one institution's experience with treatment outcomes for rectal squamous-cell carcinoma...
  21. ncbi Carcinoid of the rectum risk stratification (CaRRS): a strategy for preoperative outcome assessment
    Bridget N Fahy
    Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:396-404. 2007
    ..Predicting rectal carcinoid behavior exclusively on the basis of tumor size is imprecise. We sought to identify factors associated with outcome and incorporate them into a preoperative risk stratification scheme...
  22. ncbi A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
    Diane L Reidy-Lagunes
    Department of Medicine, Division of Solid Tumors, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 118:4795-800. 2012
    ..Therefore, the authors of this report evaluated the safety and efficacy of MK-0646, a fully human monoclonal antibody (MoAb) that binds to the IGF-1R, as monotherapy in patients with metastatic, well-differentiated NETs...
  23. ncbi The prevalence of pancreatic acinar differentiation in gastric adenocarcinoma: report of a case and immunohistochemical study of 111 additional cases
    Hwajeong Lee
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 36:402-8. 2012
    ..Thus, acinar differentiation is rare in gastric adenocarcinomas, other than in histologically unusual cases such as the one we report, and in others from the literature, which are reviewed...
  24. ncbi MET expression and amplification in patients with localized gastric cancer
    Yelena Y Janjigian
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 20:1021-7. 2011
    ..MET, the receptor for hepatocyte growth factor, has been proposed as a therapeutic target in gastric cancer. This study assessed the incidence of MET expression and gene amplification in tumors of Western patients with gastric cancer...
  25. ncbi Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:131-8. 2013
    ....
  26. ncbi A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers
    Jordan M Winter
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America corrected
    PLoS ONE 7:e40157. 2012
    ..To help researchers sort through the maze of biomarker data, a compendium of ∼2500 published candidate biomarkers in PDA was compiled (PLoS Med, 2009. 6(4) p. e1000046)...
  27. ncbi Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization
    Laura J Tafe
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Arch Pathol Lab Med 135:1460-5. 2011
    ..Patients with advanced gastroesophageal cancer have poor survival with current therapy. Human epidermal growth factor receptor 2 (HER2) represents a promising therapeutic target, but the optimal HER2 testing strategy is not yet defined...
  28. ncbi Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 39:498-505. 2008
    ..The significance of such an association as well as the prognostic value of FRalpha expression deserves further exploration...
  29. ncbi BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma
    Cristina R Ferrone
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 27:433-8. 2009
    ....
  30. ncbi Neoadjuvant therapy of locally advanced gastric cancer
    James J Mezhir
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Surg Oncol 101:305-14. 2010
    ..Early assessment of metabolic response to therapy can potentially be utilized to tailor treatment...
  31. ncbi Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis
    Deepti Dhall
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 41:643-52. 2010
    ....
  32. ncbi Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification
    Zhaohai Yang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Am J Surg Pathol 35:853-60. 2011
    ....
  33. ncbi Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer
    Inderpal S Sarkaria
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg 249:764-7. 2009
    ..We wanted to determine if endoscopic biopsy can accurately establish evidence of local pathologic complete response (pCR) in patients undergoing CRT...
  34. ncbi Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent
    Jason S Gold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:365-72. 2007
    ..Metastatic gastric cancer has a dismal prognosis. We identified a subset of patients where surgical resection with therapeutic intent was undertaken in the setting of known metastatic disease...
  35. ncbi Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors
    Diane L Reidy
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    Nat Clin Pract Oncol 6:143-52. 2009
    ..We will discuss the data on therapies currently used to treat well-differentiated NETs, and the strategies being used in clinical trials...
  36. ncbi Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6
    Laura H Tang
    Departments of Pathology and Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 18:4612-20. 2012
    ..In this study, we took a closer look at the role of the retinoblastoma pathway in human Pan-NETs...
  37. ncbi Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics
    Lurmag Orta
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 33:934-44. 2009
    ....
  38. ncbi Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa
    Rohit Bhargava
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:1857-62. 2006
    ..Either antibody may be used for immunohistochemical detection of EGFR in colorectal carcinomas. In addition, manual scoring had an excellent correlation with automated scoring...
  39. ncbi Extrahepatic bile duct carcinoid tumors: malignant biliary obstruction with a good prognosis
    Cristina R Ferrone
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 205:357-61. 2007
  40. ncbi Extranodal follicular dendritic cell sarcoma: clinical, pathologic, and histogenetic characteristics of an underrecognized disease entity
    Jinru Shia
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Virchows Arch 449:148-58. 2006
    ..The 5-year recurrence-free survival was 27.4%. From data available at the current time, we were not able to identify prognostically significant pathologic factors...
  41. ncbi Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases
    Laura H Tang
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 29:512-9. 2005
    ..The possibility that these tumors represent high-grade malignant transformation of a conventional low-grade SPT is proposed...
  42. ncbi High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease
    Derek G Power
    Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Howard 916, New York, NY 10021, USA
    Med Oncol 28:S169-74. 2011
    ..Aggressive locoregional treatment is an option in patients with extensive stage small-cell carcinoma of the colon who are left with an oligometastasis after platinum-based systemic chemotherapy...
  43. ncbi Small-cell carcinomas of the gastrointestinal tract: a review
    Baruch Brenner
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill School of Medicine, Cornell University, New York, NY 10021, USA
    J Clin Oncol 22:2730-9. 2004
    ..While chemotherapy can achieve significant palliation, surgery may have a potential impact on long-term survival of patients with locoregional disease...
  44. ncbi Utility of a prognostic nomogram designed for gastric cancer in predicting outcome of patients with R0 resected duodenal adenocarcinoma
    Jason S Gold
    Department of Surgery, VA Boston Healthcare System Brigham and Women s Hospital, West Roxbury, Massachusetts, USA
    Ann Surg Oncol 14:3159-67. 2007
    ..We tested the utility of a nomogram created for determining disease-specific survival (DSS) after R0 resection of gastric cancer in estimating DSS for patients with resected duodenal cancer...